BioCryst Pharma (BCRX) Misses Q4 EPS by 3c ; Offers Guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.4 million versus the consensus estimate of $89.97 million.

GUIDANCE:

BioCryst Pharma sees FY2024 ORLADEYO revenue of $380-400 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance